Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View
On Tuesday, Veracyte, Inc (NASDAQ:VCYT) reported second-quarter sales of $114.43 million, up 27% year over year, beating the consensus of $100.3 million.
週二，Veracyte公司（納斯達克：VCYT）公報了第二季度銷售額爲1.144.300美元，同比增長27％，超出了市場預期的1.003.000美元。
Testing revenue was $107.0 million, an increase of 31%, driven by the strong performance of our Decipher Prostate and Afirma tests.
檢測收入爲1.0700.00美元，增長了31％，由Decipher前列腺和Afirma測試的強勁表現推動。
Total test volume grew to 39,023, an increase of 23% compared to the second quarter of 2023.
總測試量增長到39,023，同比增長23％，與2023年第二季度相比。
During the quarter, the company achieved a record Decipher Prostate test volume of close to 19,900 tests, driven by recently updated NCCN prostate cancer guidelines, in which the Decipher Prostate test received the highest-level rating among gene expression tests.
在本季度，公司創造了近19,900次Decipher前列腺測試記錄，這是由於最近更新了NCCN前列腺癌指南，其中Decipher前列腺測試在基因表達測試中獲得了最高級別的評價。
The company delivered a record Afirma test volume of approximately 15,700 and received Medicare coverage for Afirma testing of patients with thyroid nodules classified as "Bethesda V," giving more patients annually access to the test.
該公司提供了約15,700張Afirma測試記錄，並承認了用於對甲狀腺結節進行“白塞德斯達V”分類的一項Medicare支付測試，從而使更多的患者可以每年接受測試。
The diagnostics company reported adjusted EPS of $0.30, up from $0.12 a year ago, beating the consensus loss of $(0.02).
該診斷公司報告的調整後每股收益爲0.30美元，去年同期爲0.12美元，超出了預期的虧損0.02美元。
Guidance: Veracyte raised its full-year 2024 revenue guidance to $432 million-$438 million, up from $402 million-$410 million and above the consensus of $406.27 million.
指導意見：Veracyte將全年2024年收入指導提高到4.3200.00-4.3800.00萬美元，高於4.0200.00-4.1000.00萬美元的先前指導，也高於市場預期的4.0627.00萬美元。
The guidance represents year-over-year growth of 20%-21% and testing revenue growth of approximately 25%, compared to prior guidance of 11%-14% and testing growth of 15%-18%.
該指導表示同比增長20％-21％，檢測收入增長約25％，而先前的指導爲11％-14％和檢測增長爲15％-18％。
The company now expects cash, cash equivalents, and short-term investments at the end of the year to be $260 million to $270 million compared to prior guidance of $236 million to $240 million.
該公司現在預計年底時的現金、現金等價物和短期投資將爲2.6000.00萬美元至2.7000.00萬美元，而先前的指導爲2.3600.00萬美元至2.4000.00萬美元。
William Blair writes, "This was an all-around very good quarter for Veracyte, and there simply is not all that much to pick at.
William Blair撰文稱：“這對Veracyte來說是一個完全沒問題的季度，沒有什麼需要吹毛求疵的。”
"Management extended its long string of quarterly beats, and the increased guidance for revenue and cash generation should highlight the company as a profitable grower in a group where few names like this exist," the analyst added.
分析師補充稱：“管理層延續了它的連續季度業績好於市場預期，而增加的收入和現金生成指導將突顯該公司作爲一家獲利增長公司群體中少有的存在。”
The analyst maintains an Outperform rating, noting the numbers going higher, and with confidence in the team's ability to execute on several growth drivers over the near and long term.
該分析師維持“跑贏大盤”的評級，並注意到數字在不斷上升，並且對團隊在不久的將來和長期內執行幾個增長驅動器的能力充滿信心。
Needham maintains Veracyte with a Buy and raises the price target from $27 to $31.
Needham維持了Veracyte的買入評級，並將價格目標從27美元上調至31美元。
Price Action: VCYT stock is up 24.60% at $27.19 at the last check on Wednesday.
價格行動：VCYT股票週三上漲24.60％至27.19美元。
- Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks.
- 生物疫苗製造商Emergent BioSolutions預計2024年虧損將加劇，股票下跌。